You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →
Orbis Medicines secures strategic investment from Novo in multi-drug deal worth up to $1.4B for oral macrocycle cardiometabolic drug development.
PRIVATESep 17, 2026•about 2 hours ago
Amount Raised
$1.4 Billion
Round Type
Corporate Round
CopenhagenBiotechnology
Investors
Novo
Description
Novo has entered into a multi-drug partnership with Danish biotech Orbis Medicines, valued at up to $1.4 billion, to develop oral macrocycle cardiometabolic drugs. As part of the deal, Novo will make a strategic investment in Orbis alongside the collaboration agreement. Orbis' AI-based nCycle platform is designed to accelerate discovery of orally available biologics using ring-shaped molecules for next-generation weight loss and cardiometabolic treatments. Novo was previously a supporter in Orbis' seed rounds and the €90 million Series A in early 2025.
Company Information
Company
Orbis Medicines
Location
Copenhagen, Capital Region Of Denmark, Denmark
About
Orbis Medicines is a biotechnology company focused on pioneering a new era for oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties, defined by the presence of a cyclic structure. Orbis’ nGen platform is designed to systematically explore the macrocycle chemical space using a highly automated chemistry platform and deliver oral macrocycle drug candidates – nCycles – suitable for both intra- and extracellular targets. Orbis’ programs are focused on high-value oral alternatives to blockbuster biologic drugs and targets challenging for established modalities.
Don't miss Orbis Medicines's next move
Get an email the moment Orbis Medicines raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
1 contact
Predictive Intelligence
Strategic
ML-powered predictions for Orbis Medicines's next move
CopenhagenBiotechnology